Hepatocellular carcinoma

This phase 1 trial tests whether a personalized vaccine made from a patient's own immune cells can safely boost the body's defenses against liver cancer. People with early-stage hepatocellular carcinoma receive either microwave ablation alone or ablation followed by seven doses o…

This study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…

Researchers test whether adding high-dose radiotherapy to standard chemoembolization slows tumor growth better than chemoembolization alone in adults with hepatocellular carcinoma. Participants have liver tumors up to 9 cm that cannot be removed by surgery or treated with percuta…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This phase 2 trial tests whether simvastatin, a widely used cholesterol-lowering drug, can prevent liver cancer in 52 adults with liver cirrhosis. Participants take simvastatin and are monitored with blood tests and imaging to see if cancer-related markers change. The goal is to …

This study tests a decision model that aims to predict whether a person with unresectable hepatocellular carcinoma, a type of liver cancer, will benefit more from transarterial chemoembolization (TACE) alone or TACE combined with atezolizumab plus bevacizumab. Researchers will de…

This study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help people with advanced liver cancer live longer than current standard treatments. About 732 participants who have not had prior systemic therapy will be randomly assigned to receiv…

This trial is testing whether a chemotherapy drug called idarubicin works as well as the standard drug doxorubicin when used in a procedure called transarterial chemoembolization (TACE) for liver cancer. TACE delivers chemotherapy directly to the tumor and blocks its blood supply…

This trial is testing whether combining a procedure that blocks blood flow to tumors (TACE) with two drugs—sintilimab, which boosts the immune system, and bevacizumab, which cuts off tumor blood supply—can safely and effectively treat liver cancer that cannot be surgically remove…

This study compares a new treatment called TheraSphere (tiny radioactive beads) to standard chemoembolization for people with liver cancer that cannot be removed by surgery. About 92 Chinese adults with early-to-mid stage liver cancer will be randomly assigned to one of the two t…

This study is testing whether giving a PD-1 inhibitor (a type of immunotherapy) after microwave ablation can help prevent early-stage liver cancer from coming back. About 200 adults with early liver cancer will receive the drug every three weeks for nine cycles. The main goal is …

This trial is testing a new abdominal compression technique to reduce breathing-related movement of liver tumors during radiation therapy. The study will compare this novel method with current compression devices and traditional thermoplastic masks in 120 adults receiving radiati…

This early-phase study tests whether combining the immune-boosting drug nivolumab with a procedure that delivers chemotherapy directly to liver tumors (called deb-TACE) is safe for people with advanced liver cancer. Twenty participants will receive the combination, and researcher…

This study tested the drug sorafenib in 50 adults with advanced liver cancer that had worsened after at least one prior treatment. Participants took sorafenib daily to see if it could slow tumor growth and improve survival. The trial measured how long patients lived without their…

This trial tests whether a device called VitaSmart, which pumps cold, oxygenated preservation fluid through a donor liver before transplant, can reduce early organ dysfunction and improve survival compared with the usual method of simply storing the liver on ice. About 228 adults…

This study investigates whether combining two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before and after surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination before surger…

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This study tests a cancer-killing virus called JX-594 (Pexa-Vec) in people with advanced liver cancer that cannot be removed by surgery. Participants receive the virus through an IV and then directly into liver tumors, followed by the standard drug sorafenib. The goal is to see i…

This phase 3 trial compares a combination of two drugs—toripalimab (an immunotherapy) and bevacizumab (an anti-angiogenic agent)—against the standard drug sorafenib as the first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolls a…

This phase II trial is testing whether a new biologic drug called PM8002, when combined with standard chemotherapy (FOLFOX), can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls about 35 adults with inoperable hepatocellular …

This phase 2 trial investigates whether combining toripalimab (an immunotherapy) with bevacizumab (a drug that cuts off tumor blood supply) can safely shrink advanced liver cancer when used as the first treatment. About 50 to 60 adults with intermediate or late-stage liver cancer…

This trial investigates whether JX-594 (Pexa-Vec), a virus modified to attack cancer cells and boost the immune system, combined with best supportive care, can help people with advanced liver cancer live longer. The study enrolls adults whose liver cancer has progressed or who co…

This study tests a combination of two drugs, pembrolizumab and bavituximab, in 35 adults with advanced liver cancer that cannot be treated with surgery or local therapies. The goal is to see if the combination shrinks tumors and improves survival. Participants must not have had p…

This study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…

This study tests whether adding a targeted drug (Donafenib) and chemotherapy directly into the liver's blood supply can prevent liver cancer from returning after surgery. It includes adults with a single large tumor (≥5 cm) and microscopic blood vessel invasion, who are at high r…

This clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…

This trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study…

This phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically re…

This study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…

This completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12…

This early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …

This study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug co…

This phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients h…

This small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatme…

This study looked at 715 patients with very large liver cancers (over 10 cm) to see if giving a combination of local treatments (like chemo directly into the liver) and body-wide treatments (targeted drugs and immunotherapy) before surgery helps them live longer. Patients were di…

This study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had worsened after standard treatments. The goal was to see if the combo could slow cancer growth and how safe it was. Results may help develop better options f…

This study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…

This completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …

This study tested a combination of two drugs (atezolizumab and bevacizumab) given before surgery to people with liver cancer. The goal was to see how well the drugs shrink the tumor and how they affect the immune system. 40 participants were enrolled, and researchers also studied…

This study looked at the safety of two drugs, IMJUDO and IMFINZI, given together or alone to 1,200 people with advanced liver cancer that cannot be removed by surgery. The main goal was to track any side effects that happen in everyday medical use. The study is now complete and h…

This study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and resu…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…

This early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The s…

This study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …

This study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…

This early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein t…

This study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if thi…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…

This study tested a combination of proton beam radiotherapy followed by two drugs (Tecentriq and Avastin) in 63 adults with advanced liver cancer that had spread into the portal vein. The goal was to see if this approach could help control the cancer and improve survival. Partici…

This pilot study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 20 adults with liver cancer that could not be surgically removed. The goal was to see if the treatment is safe and to measure how long patients survive. The approach aims to d…

This study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…

This study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …

This study looked at 200 people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. Researchers compared two second-line options: a PD-1 inhibitor combined with either lenvatinib or regorafenib. The goal was to see which combo works bet…

This study tested a new treatment for advanced liver cancer that has spread into the major blood vessels of the liver. Thirty patients received a special type of radiation along with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help pat…

This study tested a new way to destroy small liver tumors using two microwave antennas at once, compared to the standard single antenna method. Twenty patients with small hepatocellular carcinoma (liver cancer) were treated. The goal was to see if the two-antenna approach could m…

This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…

This study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One h…

This study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…

This phase 3 trial tested whether adding radiofrequency ablation (RFA) to standard transarterial chemoembolization (TACE) improves outcomes for people with intermediate-stage liver cancer. 241 participants with 2-10 liver tumors were randomly assigned to receive either TACE alone…

This phase II trial tested whether giving the immunotherapy drug tislelizumab, alone or combined with the targeted therapy lenvatinib, before surgery could help shrink liver tumors in 36 patients with resectable hepatocellular carcinoma. The main goal was to see if at least half …

This study tested a procedure called selective internal radiation therapy (SIRT) using Y-90 resin microspheres (SIR-Spheres) in one patient with liver cancer that could not be removed by surgery. The goal was to see if a flexible dosing approach could improve outcomes like tumor …

This study tested whether giving the immunotherapy drug pembrolizumab before and after a standard tumor-destroying procedure (ablation) could improve outcomes for 30 people with early-stage liver cancer. The goal was to see if the combination could shrink tumors and delay recurre…

This study tested a new combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib for people with advanced liver cancer who had not received prior treatment. The goal was to see if the combination could help patients live longer or shrink tumors more ef…

This small pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. Because it was a very early phase 1 trial with very…

This study tested a high-precision radiation treatment called stereotaxic radiotherapy (CyberKnife) in 44 adults with a single liver cancer tumor. The goal was to stop the tumor from growing for at least 18 months. Participants received three high-dose radiation sessions over 8-1…

This study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. Th…

This phase II trial tested a drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. AK112 is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth. The study measured safety and how well the drug shrank …

This study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy delivered directly to the liver (HAIC) in 30 adults with advanced liver cancer that had spread into the main portal vein. The goal was to see if the combination could improve one-year survival.…

This study tested a combination of two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), in 190 adults with advanced liver cancer that did not respond to or could not tolerate prior treatment. The goal was to see if the combination could shrink tumors and cont…

This early-stage trial tested whether combining donafinib (a targeted therapy) with an anti-PD-1 antibody (an immunotherapy) can safely prevent liver cancer from coming back after surgery. It involved 30 patients with high-risk features like microvascular invasion or multiple tum…

This study tested whether adding the cholesterol-lowering drug pravastatin to the standard cancer drug sorafenib helps people with advanced liver cancer live longer. It included 474 adults with Child-Pugh A cirrhosis whose cancer could not be cured. The main goal was to see if th…

This early-stage study tested a chemotherapy drug called idarubicin mixed with a contrast oil (lipiodol) injected directly into the liver artery for people with liver cancer that cannot be removed by surgery. The 15 participants all had cirrhosis. The goal was to find a safe dose…

This study tested whether adding pembrolizumab (an immunotherapy) to lenvatinib (a targeted therapy) works better than lenvatinib alone for people with advanced liver cancer. About 794 adults took part. The combination did not significantly improve how long patients lived or dela…

This study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…

This study tested a combination of two drugs—sorafenib (a targeted therapy) and pembrolizumab (an immunotherapy)—in 37 people with advanced liver cancer that had spread. The goal was to see if the combo could shrink tumors and help people live longer. The trial was early-stage, s…

This completed Phase 1 trial tested a new injection called NRT6003, which contains tiny radioactive beads (yttrium-90), in 40 people with liver cancer that could not be removed by surgery. The goal was to see if the treatment is safe and whether it can shrink tumors in the liver.…

This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…

This study tested whether adding a liver-directed chemotherapy infusion (HAIC) to the usual combination of lenvatinib and an immunotherapy drug (PD-1 inhibitor) helps people with advanced liver cancer that has spread into the main blood vessel of the liver. 244 patients with high…

This phase 3 trial tested whether adding focused radiation (SBRT) to the drug sorafenib helps people with advanced liver cancer live longer compared to sorafenib alone. The study enrolled 193 adults with liver cancer that could not be surgically removed. Researchers measured over…

This study tested a three-drug combination for people with advanced liver cancer that has spread into the portal vein (a major blood vessel). The treatment adds a liver-directed chemotherapy infusion to two standard drugs (lenvatinib and a PD-1 inhibitor). The goal was to see if …

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…

This study looked at 52 adults with advanced liver cancer to see if adding microwave ablation (MWA) to immunotherapy works better than immunotherapy alone. MWA uses heat to destroy tumors and may help the immune system fight cancer more effectively. The researchers measured how l…

This study looked at liver cancer patients whose tumors shrank completely after non-surgical treatments like chemoembolization and immunotherapy. Researchers compared those who then had surgery to remove any remaining tissue versus those who simply watched and waited. The goal wa…

This study tested whether adding a third drug (relatlimab) to a two-drug combination (nivolumab and bevacizumab) is safe and works better for people with advanced liver cancer who haven't had treatment before. The 83 participants received either the three-drug combo or the two-dr…

This study tested a combination of two drugs, relatlimab and nivolumab, in 266 adults with advanced liver cancer who had not received immunotherapy before but whose cancer worsened after other treatments. The goal was to see if the combination could shrink tumors or control the d…

This study looked at whether adding a mix of three drugs (thalidomide, carmofur, and a traditional Chinese medicine) to a standard procedure called TACE helps people with advanced liver cancer live longer. The study involved 545 patients and compared the combination treatment to …

This study tested a new way to make radiation therapy more effective for people with liver cancer. Doctors used special ultrasound contrast agents (tiny gas-filled microbubbles) and then 'popped' them with ultrasound waves to make tumors more sensitive to radiation. The study inv…

This study tested a new treatment for people with liver cancer that cannot be removed by surgery. The treatment combines chemotherapy delivered directly to the liver, a procedure to block the tumor's blood supply, and two drugs (lenvatinib and tislelizumab). The goal was to see i…

This study looked at side effects of the drug Cabometyx in 263 Japanese adults with advanced liver cancer that had worsened after other treatments. Doctors monitored participants for 12 months to record any serious or severe side effects. The goal was to understand the drug's saf…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced liver cancer that could not be treated with surgery. The goal was to see if these drugs could shrink tumors and control the disease. The trial included 657 adults and found that the treat…

This phase 2 trial tested a combination of two drugs—telatinib (a pill that blocks tumor blood vessels) and Keytruda (an immunotherapy that helps the immune system attack cancer)—in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see i…

This study looked at 562 people with advanced liver cancer to compare two treatment combinations: one using HAIC (chemotherapy directly into the liver) plus immunotherapy and targeted drugs, and the other using TACE (a procedure that blocks blood flow to the tumor) plus the same …

This study looked at 300 adults with high-risk liver cancer who received a combination of two drugs (atezolizumab and bevacizumab) plus chemotherapy infused directly into the liver artery. The goal was to see how well this treatment worked and how safe it was in everyday medical …

This early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…

This study looked at how safe the drug cabozantinib is for people with advanced liver cancer (hepatocellular carcinoma) who have already tried another treatment called sorafenib. A total of 110 adults took part. The main goal was to see how long patients lived after starting cabo…

This study tested a combination of two drugs, futibatinib and pembrolizumab, in 14 adults with advanced or metastatic liver cancer that had not responded to prior treatment. The goal was to see if the combination could stop or slow cancer growth. The approach uses futibatinib to …

This study tested a drug called tislelizumab in 50 people with advanced liver cancer who also have moderate liver damage (Child-Pugh B). The goal was to see if the drug could shrink tumors. Tislelizumab works by helping the immune system attack cancer cells. The study took place …

This phase 2 trial tested whether adding rivoceranib to camrelizumab after surgery or ablation helps prevent liver cancer from coming back in high-risk patients. 251 participants were randomly assigned to receive either the combination or camrelizumab alone. The main goal was to …

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested two chemotherapy drugs, cisplatin and mitomycin-C, given directly into the liver artery for people with liver cancer that cannot be surgically removed. The goal was to see how long tumors stay controlled and to track side effects. 76 participants were enrolled. …

This study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (Keytruda) in 89 people with advanced melanoma, colorectal cancer, or liver cancer. The goal was to see if the combination is safe and can shrink tumors. Some participants with liver cancer al…

This Phase 3 study tested a new immunotherapy drug, tislelizumab, against the standard targeted therapy sorafenib in 684 adults with advanced liver cancer that could not be removed by surgery. Participants received either tislelizumab intravenously every three weeks or sorafenib …

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested whether a 6-day infusion of somatostatin, a drug that lowers pressure in the liver's blood vessels, could prevent ascites (fluid buildup) after liver cancer surgery. 179 patients with liver cancer and underlying liver disease took part. The goal was to see if so…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to best supportive care helps Asian patients with advanced liver cancer live longer. 453 patients who had already received one prior treatment were randomly assigned to get either pembrolizum…

This phase 2 trial tested a new chemotherapy combination (Nal-IRI with 5-FU and leucovorin) against a standard treatment (gemcitabine plus cisplatin) in 93 people with advanced biliary tract cancer that could not be removed by surgery. The study aimed to see which approach better…

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete…

This completed Phase 3 trial tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be surgically removed and had not been treated before. The goal was to check safety and how well the treatment works. The study wa…

This study looked at 24 patients with advanced liver cancer whose disease got worse after standard treatment with lenvatinib and an immunotherapy drug. Researchers added a third drug, lenalidomide, to see if it could help control the cancer again. The goal was to measure how long…

This phase 2 trial tested colchicine, a drug usually used for gout, in 42 people with advanced liver cancer that could not be treated with curative intent. Participants took colchicine tablets daily in cycles of 4 days on, 3 days off. The study measured how long patients survived…

This study tested a new way to deliver chemo directly to liver tumors using a wrist artery instead of the groin. Thirty-eight patients with liver cancer took part. The goal was to see if the wrist approach is safe, feasible, and effective, with fewer complications and faster reco…

This study tested whether adding hydroxychloroquine (a malaria drug) to the standard cancer drug sorafenib could slow tumor growth in people with advanced liver cancer. 64 adults who were not candidates for surgery or transplant took part. The goal was to see if the combination d…

This pilot study tested the safety of giving sitagliptin (Januvia) for three weeks to 14 liver cancer patients before they had surgery to remove their tumors. The idea is that sitagliptin might help immune cells get into the tumor and fight it better. The main goal was to check f…

Researchers at Hanoi Medical University are studying whether two blood markers, AFP-L3 and PIVKA-II, can accurately detect hepatocellular carcinoma, the most common form of liver cancer. The trial enrolls 200 adults, including people with liver cancer and people with benign liver…

This trial is testing whether a special PET/CT scan, typically used for prostate cancer, can better detect hepatocellular carcinoma (the most common type of liver cancer) compared to standard CT or MRI scans. The study will enroll about 30 adults with liver lesions suspicious for…

This study tested a special PET/MRI scan that uses a radioactive tracer to find liver cancer cells. The goal was to see if this scan can detect liver cancer earlier and more accurately than standard scans. 52 adults with liver cancer took part, and researchers compared the new sc…

This study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each …

This completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …

This study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …

This study tested a new artificial intelligence (AI) algorithm against the standard LI-RADS criteria for diagnosing liver cancer (hepatocellular carcinoma) on CT scans. Researchers enrolled 300 people at risk for liver cancer who had a new liver nodule found on ultrasound. The go…

This study looked at blood samples from 573 people to find new markers that could diagnose liver cancer more accurately. Researchers compared samples from patients with liver cancer, those with other liver conditions, and people with hepatitis infections. The goal is to improve u…

This study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…

This study tested whether a shorter, contrast-enhanced MRI (called AMRI) is better than standard ultrasound for finding liver cancer early in people with cirrhosis. 79 adults with cirrhosis underwent both scans, and researchers compared how accurately each method detected cancer.…

This study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer (hepatocellular carcinoma) in people with hepatitis C. Researchers tested blood samples from 84 participants, including healthy people and those with hepatitis C, wi…

This phase 2 trial tested whether a special PET scan using a radioactive tracer called 68Ga-PSMA can better detect advanced liver cancer that has spread. The tracer attaches to a protein found on liver cancer cells, making them visible on the scan. The study involved 29 adults wi…

This study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…

This large completed trial tested whether an AI system can help radiologists better diagnose liver tumors from CT scans. Over 10,000 adults with various liver conditions participated. The AI analyzed scans overnight, and a senior radiologist reviewed any differences between the A…

This clinical trial investigates whether two existing medications, allopurinol and atorvastatin, can help prevent serious complications in people with stable liver cirrhosis. The study will compare these drugs against a placebo to see if they reduce the number of acute decompensa…

This study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…

This study tested whether giving a single dose of pregabalin before a liver cancer ablation procedure can reduce pain afterward. 70 adults with liver cancer were randomly assigned to receive either pregabalin or a placebo before their procedure. The main goal was to measure pain …

This phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …

This study tested whether a personalized diet plan helps liver cancer patients eat more and recover faster after surgery. 139 patients who had part of their liver removed were split into two groups: one got standard care, the other got a custom meal plan with extra protein drinks…

This study looked at whether a combination of two pain medicines (hydromorphone and flurbiprofen) could help control pain during and after a liver cancer treatment called TACE. 129 adults with intermediate-to-advanced liver cancer took part. The goal was to see if this approach c…

This study tested two approaches to bring palliative care (comfort-focused care) to people with end-stage liver disease. About 1,500 adults from 19 U.S. centers took part. One group had direct access to a palliative care specialist; the other group saw a liver doctor specially tr…

This study looked at whether taking zinc supplements can improve quality of life for people with advanced gastrointestinal cancers (like stomach, liver, or pancreatic cancer) who are receiving chemotherapy. Seventeen patients participated, and researchers measured their quality o…

This study tested whether taking zinc supplements and applying a strong steroid cream (clobetasol) can prevent or reduce hand-foot skin reaction, a common and painful side effect of the cancer drug regorafenib. About 150 patients starting regorafenib were split into three groups:…

This study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…

This study gathers blood, urine, stool, and tissue samples from 132 adults with primary liver cancer who are receiving or have received immunotherapy. Researchers will analyze these samples along with medical records to learn more about how liver cancer develops and responds to t…

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study looks at how two heat-based procedures — radiofrequency ablation and microwave ablation — affect the immune system in people with small liver cancers. Researchers will take blood samples and tissue biopsies before and after treatment to track changes in immune cells. T…

This study compares two catheters used during the mapping step before radioembolization for liver cancer. One is a standard microcatheter, the other is a pressure-enabled device (TriNav). The goal is to see if the pressure-enabled catheter delivers more radioactive tracer directl…

This study developed an artificial intelligence model that analyzes MRI scans and pathology images to predict the risk of liver cancer returning after surgery. Researchers used data from over 500 patients who had their liver cancer surgically removed. The goal is to help doctors …

This study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor …

This study looks at whether simple, non-invasive blood test scores can predict the risk of developing liver cancer in people with advanced liver disease who have been cured of hepatitis C. Researchers analyzed data from 571 adults treated at a single hospital over ten years. The …

This study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…

This study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …

This study looked at 153 people having liver cancer surgery to see if the type of anesthesia they received affected their recovery and immune response. Researchers compared different anesthesia methods and measured blood markers related to inflammation and immune cell activity. P…

This completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…

This completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…

This study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowl…

This study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…

This study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researc…

This registry followed over 1,000 liver cancer patients who received SIR-Spheres—tiny radioactive beads injected into the liver's blood supply to kill tumors. The goal was to see how this treatment is used in real hospitals and how it affects survival, side effects, and quality o…

This study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…

This study tested whether having patients stand during an ultrasound helps doctors see small liver tumors near the diaphragm that are often missed when lying down. Researchers scanned 95 people with confirmed liver lesions in three positions: standing, lying on their back, and ly…

This study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…

This study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…

This study looked at 211 people with liver cirrhosis to see which screening method works better for detecting liver cancer: an ultrasound every 6 months or an MRI once a year. Participants received both tests, and researchers measured how often each test correctly found cancer. T…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looked at liver cancer cells from 30 patients to understand how they differ from healthy cells. Researchers isolated these cells to create 3D lab models called organoids. The goal was to learn more about the behavior and genetics of liver cancer, not to test a new trea…

This study tested a computer model that helps surgeons decide the best type of surgery for patients with a rare form of liver cancer that has spread into the bile ducts. The model uses patient scans and medical history to recommend whether to remove part of the bile duct or just …

This study looked at how safe and effective a combination of two drugs (Atezolizumab and Bevacizumab) is for people with liver cancer and cirrhosis, compared to standard pills (tyrosine kinase inhibitors). Researchers followed 38 patients to see how long they lived and how their …

This study looked at 324 adults with intermediate-stage liver cancer to see if CT scan features could predict how well they would respond to a combination treatment of targeted therapy and a procedure that blocks the tumor's blood supply. The goal was to find out if certain scan …

This study looked at how safe and effective a precise type of radiation therapy (SBRT) is for treating liver tumors, liver metastases, and pancreatic tumors. It involved 65 adult patients who were already scheduled for SBRT. The goal was to monitor and improve the treatment proce…

This study looked back at data from 484 liver cancer patients who had a liver transplant to see if taking certain cancer drugs (tyrosine kinase inhibitors) before the transplant helped them live longer or kept the cancer from coming back. The researchers checked survival rates, c…

This study looked at whether liver cancer spreads differently in men and women. Researchers analyzed data from over 19,000 patients and used computer models to create separate prediction tools for each gender. The goal was to better understand risk factors for cancer spread at th…

This study analyzed medical images and data from 3000 patients with advanced liver cancer that cannot be removed by surgery. Researchers used an AI technique called radiomics to see if they could identify which patients would respond better to one of two standard treatments: TACE…

This completed study used artificial intelligence to examine CT scans from 274 liver cancer patients who had already received radiation therapy. The goal was to find the radiation dose that causes a visible liver reaction, which could help doctors avoid liver injury in future tre…

This study looked for proteins in the blood that might predict how well liver cancer treatments work. Researchers took blood samples from 17 patients before and after standard treatments like TACE or ablation. The goal was to find biomarkers that could help doctors choose the bes…

This study tested a new way of helping patients breathe during a procedure that destroys liver tumors with heat or electricity. The new method, called flow-controlled ventilation, keeps the diaphragm more still than standard methods, which could help doctors place needles more ac…

This study looked at how a combination of two drugs (atezolizumab and bevacizumab) works on liver cancer tumors in different parts of the body. Researchers wanted to see if the drugs work better on tumors in some organs than others. The study included 131 people with advanced liv…

This completed study looked at the genetic makeup of liver cancer in 808 patients to better understand the disease. Researchers analyzed tumor samples from people treated with surgery, ablation, or transplant, as well as those with advanced cancer. The goal was to identify key ge…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This completed study aimed to create a biobank of 'organoids'—tiny, 3D mini-tumors grown from liver cancer tissue. Researchers collected samples from 48 patients with colorectal cancer that spread to the liver or with primary liver cancer. The goal was to see if they could reliab…

This study looked at over 1000 liver cancer patients who had surgery to remove their tumors. Researchers developed a model using tumor size, number of tumors, and a blood marker (AFP) to predict 5-year survival. They also compared outcomes between open and laparoscopic surgery, a…

This study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…

This study looked at 379 people with liver cancer to see if monitoring changes in blood markers over time could help doctors better predict how the disease will progress. Researchers combined these marker trends with patient information to build a more accurate risk model. The go…

This study reviewed medical records of 300 liver cancer patients treated in Brazil between 2017 and 2022. Researchers aimed to understand patient characteristics, how the cancer was managed, and survival outcomes. No new treatments were tested; instead, the goal was to gather rea…

This study tested the EchoTip AcuCore, a needle used during endoscopic ultrasound to collect tissue samples from the pancreas, liver, and other organs. 183 adults with conditions like cancer or chronic pancreatitis took part. The main goal was to see if the needle could get a goo…

This completed study analyzed tumor and blood samples from 166 people with advanced liver cancer who received a combination of atezolizumab and bevacizumab. The goal was to find biomarkers—biological clues—that could predict how well a patient responds to treatment and how long t…

This completed study used artificial intelligence to analyze data from 7,000 liver cancer patients. The goal was to create a tool that helps doctors predict liver function, treatment outcomes, and cancer spread. The tool aims to guide personalized decisions about surgery, chemoth…